Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STILL-GLORY: Luseogliflozin vs Dulaglutide after PCI in Type 2 Diabetes
jRCTs031180408Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Jun 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis and acute coronary syndrome (ACS) comparing Luseogliflozin arm with Dulaglutide arm (2 arms). Primary endpoint: Regression of atheromatous atherosclerotic plaque by IVUS in coronary artery. Started Jun 2017; status: recruiting.
02
Drugs
luseogliflozindulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on jRCTs031180408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180408.